Gout - Current diagnosis and treatment;Gicht - Aktuelle aspekte in diagnostik und therapie

Deutsches Arzteblatt

Volumn 106, Issue 34-35, 2009, Pages 549-555

  Tausche, Anne Kathrin ^a   Jansen, Tim L ^c   Schröder, Hans Egbert ^a   Bornstein, Stefan R ^a   Aringer, Martin ^a   Müller Ladner, Ulf ^b  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c Abteilung Rheumatologie   (Netherlands)

Author keywords

Allopurinol; Deposits of uric acid; Gout; Hyperuricemia; Treatment

Indexed keywords

ALLOPURINOL; BENZBROMARONE; COLCHICINE; GLUCOCORTICOID; NONSTEROID ANTIINFLAMMATORY AGENT; URIC ACID;

GOUT; HUMAN; HYPERURICEMIA; INFLAMMATION; LONG TERM CARE; PROPHYLAXIS; REVIEW; TREATMENT INDICATION; TREATMENT PLANNING; URIC ACID BLOOD LEVEL;

EVIDENCE-BASED MEDICINE; GERMANY; GOUT; HUMANS; PHYSICIAN'S PRACTICE PATTERNS;

EID: 70349759680     PISSN: 00121207     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2009.0549     Document Type: Review

References (69)

1. Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Schumacher HR Jr, Saag KG: Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis 2005; 64: 267-272
2. Annemans L, Spaepen E, Gaskin M, et al.: Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis 2008; 67: 960-966
3. Campion EW, Glynn RJ, DeLabry LO: Asymptomatic hyperuricemia. Risks and consequences in the normative aging study. Am J Med 1987; 82: 421-426
4. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G: Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004; 350: 1093-1103 (Pubitemid 38298989)
5. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G: Alcohol intake and risk of incident gout in men: a prospective study. Lancet 2004; 363: 1277-1281 (Pubitemid 38496489)
6. Alamanos Y, Voulgari PV, Drosos AA : Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum 2006; 36: 182-188
7. Tausche AK, Unger S, Richter K, et al.: Hyperuricemia and gout: diagnosis and therapy. Internist (Berl) 2006; 47: 509-522
8. Zhang W, Doherty M, Pascual E et al.: EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1301-1311 (Pubitemid 44641591)
9. Zhang W, Doherty M, Bardin T et al.: EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1312-1324 (Pubitemid 44620440)
10. Unger S, Tausche AK, Kopprasch S, Bornstein SR, Aringer M, Grässler J: Molecular basis of primary renal hyperuricemia: role of the human urate transporter hURAT1. Z Rheumatol 2007; 66: 58-61. (Pubitemid 350132249)
11. Graessler J, Graessler A, Unger S et al.: Association of the human urate transporter 1 with reduced renal uric acid excretion and hyperuricemia in a German Caucasian population. Arthritis Rheum 2006; 54: 292-300. (Pubitemid 43124109)
12. Graessler J, Unger S, Tausche AK, Kopprasch S, Bornstein SR: Gout - new insights into a forgotten disease. Horm Metab Res 2006; 38: 203-204
13. Choi HK, Mount DB, Reginato AM: American College of Physicians; American Physiological Society: Pathogenesis of gout. Ann Intern Med 2005; 143: 499-516.
14. Harris MD, Siegel LB, Alloway JA: Gout and hyperuricemia. Am Fam Physician 1999; 59: 925-934
15. Urano W, Yamanaka H, Tsutani H et al.: The inflammatory process in the mechanism of decreased serum uric acid concentrations during acute gouty arthritis. J Rheumatol. 2002; 29: 1950-1953 (Pubitemid 34988705)
16. Wortmann RL: The management of gout: it should be crystal clear. J Rheumatol 2006; 33: 1921.
17. McGill NW: Gout and other crystal-associated arthropathies. Baillieres Best Pract Res Clin Rheumatol 2000; 14: 445-460
18. Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA: Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004; 31: 2429-2432
19. Jordan KM, Cameron JS, Snaith M et al.: British Society for Rheumatology and British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group (SGAWG): British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 2007; 46: 1372-1374
20. Lumbreras B, Pascual E, Frasquet J, González-Salinas J, Rodríguez E, Hernández-Aguado I: Analysis for crystals in synovial fluid: training of the analysts results in high consistency. Ann Rheum Dis 2005; 64: 612-615 (Pubitemid 40469093)
21. Shekarriz B, Stoller ML: Uric acid nephrolithiasis: current concepts and controversies. J Urol. 2002;168: 1307-1314 (Pubitemid 35034113)
22. Kramer HJ, Choi HK, Atkinson K, Stampfer M, Curhan GC: The association between gout and nephrolithiasis in men: The Health Professionals' Follow-Up Study. Kidney Int 2003; 64: 1022-1026 (Pubitemid 37013838)
23. Hande KR, Noone RM, Stone WJ: Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984; 76:47-56.
24. Tausche AK, Aringer M, Schroeder HE, Bornstein SR, Wunderlich C, Wozel G: The janus faces of allopurinol - allopurinol hypersensitivity syndrome. Am J Med 2008; 121: e3-4. (Pubitemid 351317921)
25. Perez-Ruiz F, Atxotegi J, Hernando I, Calabozo M, Nolla JM: Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study. Arthritis Rheum 2006; 55: 786-790 (Pubitemid 44619193)
26. Feig DI, Kang DH, Johnson RJ: Uric acid and cardiovascular risk. N Engl J Med 2008; 359: 1811-1821
27. Brand FN, McGee DL, Kannel WB, Stokes J 3rd, Castelli WP: Hyperuricemia as a risk factor of coronary heart disease: The Framingham Study. Am J Epidemiol 1985; 121: 11-18
28. Julius U, Schulze J, Hanefeld M: Ätiologie und Pathogenese des Metabolischen Syndroms. Diabetes und Stoffwechsel 2005; 14: 333-349
29. Schröder HE: Gicht. In: Hartmann F, Philipp T (Hrsg.): Klinik der Gegenwart. München, Wien, Baltimore: Urban und Schwarzenberg 1993; 1-48.
30. Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R: Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 2004; 31: 1582-1587
31. Weaver AL: Epidemiology of gout. Cleve Clin J Med 2008; 75: 9-12.
32. Saag KG, Choi H: Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res Ther 2006; 8: 2.
33. Vitart V, Rudan I, Hayward C et al.: SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 2008; 40: 437-442
34. Aringer M, Graessler J: Understanding deficient elimination of uric acid. Lancet 2008; 372: 1929-1930
35. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J: Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440: 237-241
36. Pétrilli V, Dostert C, Muruve DA, Tschopp J: The inflammasome: a danger sensing complex triggering innate immunity. Curr Opin Immunol 2007; 19: 615-622
37. Dalbeth N, Haskard DO: Inflammation and tissue damage in crystal deposition diseases. Curr Opin Rheumatol 2005; 17: 314-318
38. Rose DM, Liu-Bryan R: Innate immunity in triggering and resolution of acute gouty inflammation. Curr Rheumatol Rep 2006; 8: 209-214
39. Bellamy N, Downie WW, Buchanan WW: Observations on spontaneous improvement in patients with podagra: implications for therapeutic trials of non-steroidal anti-inflammatory drugs. Br J Clin Pharmacol 1987; 24: 33-36
40. Smyth CJ: Disorders associated with hyperuricemia. Arthritis Rheum 1975; 18: 713-719
41. Schueller-Weidekamm C, Schueller G, Aringer M, Weber M, Kainberger F: Impact of sonography in gouty arthritis: Comparison with conventional radiography, clinical examination, and laboratory findings. Eur J Radiol 2007; 62: 437-442.
42. Puig JG, de Miguel E, Castillo MC, Rocha AL, Martínez MA, Torres RJ: Asymptomatic hyperuricemia: impact of ultrasonography. Nucleosides Nucleotides Nucleic Acids 2008; 27: 592-595
43. Loebl WY, Scott JT: Withdrawal of allopurinol in patients with gout. Ann Rheum Dis 1974; 33: 304-307
44. Li-Yu J, Clayburne G, Sieck M et al.: Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol 2001; 28: 577-580
45. Shoji A, Yamanaka H, Kamatani N: A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004; 51: 321-325
46. Rubin BR, Burton R, Navarra S, et al.: Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum 2004; 50: 598-606.
47. Scheiman JM: Prevention of NSAID-induced ulcers. Curr Treat Options Gastroenterol 2008; 11: 125-134
48. Ahern MJ, Reid C, Gordon TP, McCredie M, Brooks PM, Jones M: Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med 1987; 17: 301-304
49. Nuki G: Colchicine: its mechanism of action and efficacy in crystal-induced inflammation. Curr Rheumatol Rep 2008; 10: 218-227
50. Sutaria S, Katbamna R, Underwood M: Effectiveness of interventions for the treatment of acute and prevention of recurrent gout - a systematic review. Rheumatology (Oxford) 2006; 45: 1422-1431
51. Janssens HJ, Janssen M, van de Lisdonk EH, van Riel PL, van Weel C: Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet 2008; 371: 1854-1860
52. Williams PT: Effects of diet, physical activity and performance, and body weight on incident gout in ostensibly healthy, vigorously active men. Am J Clin Nutr 2008; 87: 1480-1487
53. Gibson T, Rodgers V, Potter C, Simmonds HA: Allopurinol treatment and its effect on renal function in gout: a controlled study. Ann Rheum Dis 1982; 41: 59-65.
54. Ferraz MB, O'Brien B: A cost effectiveness analysis of urate lowering drugs in nontophaceous recurrent gouty arthritis. J Rheumatol 1995; 22: 908-914
55. Delbarre F, Amor B, Auscher C, de Gery A: Treatment of gout with allopurinol. A study of 106 cases. Ann Rheum Dis 1966; 25: 627-633
56. Yu TF: The effect of allopurinol in primary and secondary gout. Arthritis Rheum 1965; 8: 905-906
57. Lupton GP, Odom RB: The allopurinol hypersensitivity syndrome. Am Acad Dermatol 1979; 1: 365-374.
58. Singer JZ, Wallace SL: The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality. Arthritis Rheum 1986; 29: 82-87.
59. Lee HY, Ariyasinghe JT, Thirumoorthy T: Allopurinol hypersensitivity syndrome: a preventable severe cutaneous adverse reaction? Singapore Med J 2008; 49: 384-387
60. Pak CY, Sakhaee K, Fuller C: Successful management of uric acid nephrolithiasis with potassium citrate. Kidney Int 1986; 30: 422-428
61. Reinders MK, van Roon EN, Jansen TL et al.: Efficacy and tolerability of urate lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis 2009; 68: 51-56
62. Paulus HE, Schlosstein LH, Godfrey RG, Klinenberg JR, Bluestone R: Prophylactic colchicine therapy of intercritical gout. A placebo-controlled study of probenecid-treated patients. Arthritis Rheum 1974; 17: 609-614
63. Pascual E, Sivera F: Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Ann Rheum Dis 2007; 66: 1056-1058
64. Gast LF: Withdrawal of longterm antihyperuricemic therapy in tophaceous gout. Clin Rheumatol 1987; 6: 70-73
65. Lieshout-Zuidema MF, Breedveld FC: Withdrawal of longterm antihyperuricemic therapy in tophaceous gout. J Rheumatol 1993; 20: 1383-1385
66. Becker MA, Schumacher HR, Wortmann RL et al.: Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353: 2450-2461
67. Hair PI, McCormack PL, Keating GM: Febuxostat. Drugs 2008; 68: 1865-1874
68. Fels E, Sundy JS: Refractory gout: what is it and what to do about it? Curr Opin Rheumatol 2008; 20: 198-202.
69. Sundy JS, Becker MA, Baraf HS, et al.: Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: Results of a phase II randomized study. Arthritis Rheum 2008; 58: 2882-2891